SK bioscience Co.,Ltd. (302440.KS)
KRW 54700.0
(-5.36%)
KRW 54700.0
(-5.36%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 142.24 Billion KRW | -43.07% |
| 2022 | 239.61 Billion KRW | -57.98% |
| 2021 | 570.28 Billion KRW | 498.14% |
| 2020 | 95.34 Billion KRW | 22.45% |
| 2019 | 77.85 Billion KRW | 98.54% |
| 2018 | 39.21 Billion KRW | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 3.71 Billion KRW | -86.6% |
| 2024 Q2 | 16.38 Billion KRW | 341.71% |
| 2024 Q3 | 61.64 Billion KRW | -88.85% |
| 2023 Q2 | 6.48 Billion KRW | 632.19% |
| 2023 Q1 | 885.12 Million KRW | -98.19% |
| 2023 Q3 | 105.48 Billion KRW | 1527.62% |
| 2023 Q4 | 27.68 Billion KRW | -73.75% |
| 2023 FY | 136.4 Billion KRW | -43.07% |
| 2022 FY | 239.61 Billion KRW | -57.98% |
| 2022 Q4 | 48.77 Billion KRW | -12.56% |
| 2022 Q3 | 55.78 Billion KRW | -35.24% |
| 2022 Q2 | 86.14 Billion KRW | 80.19% |
| 2022 Q1 | 47.8 Billion KRW | -83.08% |
| 2021 Q1 | 73.4 Billion KRW | 138.97% |
| 2021 FY | 570.28 Billion KRW | 498.14% |
| 2021 Q4 | 282.48 Billion KRW | 115.06% |
| 2021 Q3 | 131.35 Billion KRW | 58.18% |
| 2021 Q2 | 83.03 Billion KRW | 13.13% |
| 2020 FY | 95.34 Billion KRW | 22.45% |
| 2020 Q2 | 8.58 Billion KRW | 31.72% |
| 2020 Q3 | 51.69 Billion KRW | 502.17% |
| 2020 Q4 | 30.71 Billion KRW | -40.58% |
| 2020 Q1 | 6.51 Billion KRW | -68.51% |
| 2019 FY | 77.85 Billion KRW | 98.54% |
| 2019 Q4 | 20.69 Billion KRW | -3.51% |
| 2019 Q3 | 21.45 Billion KRW | -30.75% |
| 2019 Q2 | 30.97 Billion KRW | 554.17% |
| 2019 Q1 | 4.73 Billion KRW | -72.99% |
| 2018 Q4 | 17.53 Billion KRW | -19.13% |
| 2018 FY | 39.21 Billion KRW | 0.0% |
| 2018 Q3 | 21.68 Billion KRW | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| ORIENT BIO Inc. | 9.58 Billion KRW | -1384.107% |
| Green Cross Holdings Corporation | 603.58 Billion KRW | 76.434% |
| Green Cross Holdings Corporation | 458.68 Billion KRW | 68.989% |
| Pharmicell Co., Ltd. | 14.95 Billion KRW | -851.127% |
| Green Cross Corporation | 458.68 Billion KRW | 68.989% |
| GeneOne Life Science, Inc. | -14.98 Billion KRW | 1049.278% |
| Celltrion, Inc. | 1010.9 Billion KRW | 85.929% |
| Samsung Biologics Co.,Ltd. | 1802.76 Billion KRW | 92.11% |
| SK Biopharmaceuticals Co., Ltd. | 308.37 Billion KRW | 53.873% |
| Prestige BioPharma Limited | 689.07 Million KRW | -20542.572% |